Los Angeles Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Los Angeles Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$127K	Sell	28,511 -4,407	-13%	-$20.5K	﹤0.01%	1273
2025 Q4	$162K	Buy	+32,918	New	+$160K	﹤0.01%	1303
2025 Q3	–	Sell	-117,740	Closed	-$272K	–	1537
2025 Q2	$272K	Sell	117,740 -25,070	-18%	-$54.5K	﹤0.01%	1088
2025 Q1	$199K	Buy	142,810 +5,350	+4%	+$8.95K	﹤0.01%	1013
2024 Q4	$238K	Sell	137,460 -69,532	-34%	-$144K	﹤0.01%	1008
2024 Q3	$416K	Buy	+206,992	New	+$454K	﹤0.01%	914

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Los Angeles Capital Management's TSHA Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Taysha Gene Therapies (TSHA) stake by 13% in Q1 2026, selling an estimated $20.5K and leaving 28,511 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1273.

Los Angeles Capital Management first reported a position in TSHA in Q3 2024 and has held it in 6 quarters since. The position peaked at $416K in Q3 2024. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Los Angeles Capital Management held 28,511 shares of Taysha Gene Therapies worth $127K as of Q1 2026.
Los Angeles Capital Management sold 4,407 Taysha Gene Therapies shares in Q1 2026, an estimated $20.5K.
Taysha Gene Therapies made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1273 holding.
Los Angeles Capital Management first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 6 quarters since.
Los Angeles Capital Management's Taysha Gene Therapies position peaked at $416K in Q3 2024.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.